TW201444870A - 高度半乳糖基化的抗ｈｅｒ２抗體及其用途 - Google Patents
高度半乳糖基化的抗ｈｅｒ２抗體及其用途 Download PDFInfo
- Publication number
- TW201444870A TW201444870A TW103104772A TW103104772A TW201444870A TW 201444870 A TW201444870 A TW 201444870A TW 103104772 A TW103104772 A TW 103104772A TW 103104772 A TW103104772 A TW 103104772A TW 201444870 A TW201444870 A TW 201444870A
- Authority
- TW
- Taiwan
- Prior art keywords
- antibody
- population
- composition
- antibodies
- produced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/12—Immunoglobulins specific features characterized by their source of isolation or production isolated from milk
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Epidemiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Botany (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764488P | 2013-02-13 | 2013-02-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201444870A true TW201444870A (zh) | 2014-12-01 |
Family
ID=50980322
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW103104772A TW201444870A (zh) | 2013-02-13 | 2014-02-13 | 高度半乳糖基化的抗ｈｅｒ２抗體及其用途 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150368357A1 (enExample) |
| EP (1) | EP2956485A2 (enExample) |
| JP (2) | JP2016509019A (enExample) |
| KR (1) | KR20160003634A (enExample) |
| CN (1) | CN105308071A (enExample) |
| AR (1) | AR094781A1 (enExample) |
| AU (1) | AU2014217564B2 (enExample) |
| BR (1) | BR112015019343A2 (enExample) |
| CA (1) | CA2900912A1 (enExample) |
| IL (1) | IL240440A0 (enExample) |
| MX (1) | MX2015010428A (enExample) |
| TW (1) | TW201444870A (enExample) |
| WO (1) | WO2014125377A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG191781A1 (en) | 2010-12-30 | 2013-08-30 | Lab Francais Du Fractionnement | Glycols as pathogen inactivating agents |
| BR112015019348A2 (pt) | 2013-02-13 | 2017-08-22 | Lab Francais Du Fractionnement | Métodos para produção de proteína com glicosilação modificada e com sialilação aumentada, para aumentar a atividade de sialil transferase na glândula mamária e para produzir sialil transferase, proteína com glicosilação modificada ou proteína com sialilação aumentada, composição, sialil transferase, mamífero transgênico, e, célula epitelial mamária |
| AU2014217561B2 (en) | 2013-02-13 | 2018-11-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-alpha antibodies and uses thereof |
| US10611826B2 (en) | 2013-07-05 | 2020-04-07 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
| EP3191527B1 (en) * | 2014-09-10 | 2020-01-15 | F.Hoffmann-La Roche Ag | Galactoengineered immunoglobulin 1 antibodies |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| CN105669964B (zh) * | 2016-03-04 | 2017-11-21 | 博瑞生物医药（苏州）股份有限公司 | 卵巢癌特异靶向的生物可降解双亲性聚合物、由其制备的聚合物囊泡及应用 |
| FR3060395B1 (fr) * | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-her2 |
| AU2019282264A1 (en) * | 2018-06-05 | 2020-11-26 | Amgen Inc. | Modulating antibody dependent cellular phagocytosis |
| US12103978B2 (en) | 2018-06-15 | 2024-10-01 | Shanghai Miracogen Inc. | Methods and materials for treating cancer |
| EP4190818A4 (en) * | 2020-07-28 | 2024-08-07 | Bio-Thera Solutions, Ltd. | ANTI-HER2 ANTIBODY AND ITS USE |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| EP0690452A3 (en) | 1994-06-28 | 1999-01-07 | Advanced Micro Devices, Inc. | Electrically erasable memory and method of erasure |
| US5843705A (en) | 1995-02-21 | 1998-12-01 | Genzyme Transgenic Corporation | Transgenically produced antithrombin III |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| AU3657899A (en) * | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
| EP2042196B1 (en) * | 2001-10-10 | 2016-07-13 | ratiopharm GmbH | Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| US20040101939A1 (en) * | 2002-11-22 | 2004-05-27 | Santora Ling C. | Method for reducing or preventing modification of a polypeptide in solution |
| FR2861080B1 (fr) * | 2003-10-20 | 2006-02-17 | Lab Francais Du Fractionnement | Anticorps presentant un taux de fucose et de galactose optimise |
| US20060127950A1 (en) | 2004-04-15 | 2006-06-15 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| US20060057638A1 (en) | 2004-04-15 | 2006-03-16 | Massachusetts Institute Of Technology | Methods and products related to the improved analysis of carbohydrates |
| WO2006040153A2 (en) | 2004-10-13 | 2006-04-20 | Ablynx N.V. | Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease |
| US20060182744A1 (en) * | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
| AU2006249144B2 (en) | 2005-05-18 | 2011-11-17 | Ablynx Nv | Improved NanobodiesTM against Tumor Necrosis Factor-alpha |
| ES2417147T3 (es) | 2005-10-21 | 2013-08-06 | Revo Biologics, Inc. | Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso |
| EP2035034A4 (en) * | 2006-06-09 | 2009-11-18 | Univ Maryland | GLYCOSYLATION-CONTROLLED ANTIBODY THERAPY |
| JP5638804B2 (ja) * | 2006-08-04 | 2014-12-10 | アストラゼネカ アクチボラグ | ＥｒｂＢ２に対する抗体 |
| PT2073842E (pt) * | 2006-09-10 | 2015-04-07 | Glycotope Gmbh | Utilização de células humanas provenientes de uma leucemia mielóide para expressão de anticorpos |
| CN101588817B (zh) * | 2006-09-10 | 2013-06-12 | 葛莱高托普有限公司 | 骨髓白血病来源的细胞在抗体表达中的用途 |
| EP2244735A4 (en) * | 2007-10-02 | 2011-02-23 | Avaxia Biologics Inc | ANTIBODY THERAPY FOR USE IN THE DIGESTIVE TUBE |
| CN102216452B (zh) * | 2008-09-26 | 2013-08-21 | 尤里卡治疗公司 | 具有变异糖基化方式的细胞系和蛋白质 |
| WO2012105699A1 (ja) * | 2011-02-03 | 2012-08-09 | 株式会社イーベック | 補体依存性生物活性の高い抗体の産生法 |
| US8809017B2 (en) * | 2011-05-24 | 2014-08-19 | Agency For Science, Technology And Research | IRES mediated multicistronic vectors |
| AU2014217561B2 (en) * | 2013-02-13 | 2018-11-15 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-TNF-alpha antibodies and uses thereof |
-
2014
- 2014-02-13 CN CN201480020373.3A patent/CN105308071A/zh active Pending
- 2014-02-13 MX MX2015010428A patent/MX2015010428A/es unknown
- 2014-02-13 US US14/767,120 patent/US20150368357A1/en not_active Abandoned
- 2014-02-13 KR KR1020157024975A patent/KR20160003634A/ko not_active Withdrawn
- 2014-02-13 WO PCT/IB2014/000711 patent/WO2014125377A2/en not_active Ceased
- 2014-02-13 CA CA2900912A patent/CA2900912A1/en not_active Abandoned
- 2014-02-13 AR ARP140100460A patent/AR094781A1/es unknown
- 2014-02-13 JP JP2015557533A patent/JP2016509019A/ja active Pending
- 2014-02-13 BR BR112015019343A patent/BR112015019343A2/pt not_active Application Discontinuation
- 2014-02-13 TW TW103104772A patent/TW201444870A/zh unknown
- 2014-02-13 AU AU2014217564A patent/AU2014217564B2/en not_active Ceased
- 2014-02-13 EP EP14732000.6A patent/EP2956485A2/en not_active Withdrawn
-
2015
- 2015-08-09 IL IL240440A patent/IL240440A0/en unknown
-
2019
- 2019-12-27 JP JP2019238917A patent/JP2020125286A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015010428A (es) | 2016-04-13 |
| WO2014125377A2 (en) | 2014-08-21 |
| EP2956485A2 (en) | 2015-12-23 |
| IL240440A0 (en) | 2015-09-24 |
| JP2016509019A (ja) | 2016-03-24 |
| AU2014217564B2 (en) | 2018-11-08 |
| JP2020125286A (ja) | 2020-08-20 |
| CA2900912A1 (en) | 2014-08-21 |
| CN105308071A (zh) | 2016-02-03 |
| KR20160003634A (ko) | 2016-01-11 |
| AU2014217564A1 (en) | 2015-08-27 |
| US20150368357A1 (en) | 2015-12-24 |
| AR094781A1 (es) | 2015-08-26 |
| WO2014125377A3 (en) | 2014-12-04 |
| BR112015019343A2 (pt) | 2017-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020125286A (ja) | 高ガラクトシル化抗ｈｅｒ２抗体およびその使用 | |
| JP2020073550A (ja) | 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用 | |
| JP6433786B2 (ja) | 高度ガラクトシル化抗体 | |
| ES2574826T3 (es) | Procedimiento para controlar la actividad de una molécula inmunofuncional | |
| CN101484470B (zh) | 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途 | |
| JP2016513105A (ja) | 改変グリコシル化を有するセツキシマブおよびその使用 | |
| KR20220116255A (ko) | 비-푸코실화 항체의 제조를 위한 푸코실화 억제제의 용도 | |
| AU2012293420B2 (en) | Highly galactosylated antibodies |